JP2018538280A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538280A5
JP2018538280A5 JP2018526676A JP2018526676A JP2018538280A5 JP 2018538280 A5 JP2018538280 A5 JP 2018538280A5 JP 2018526676 A JP2018526676 A JP 2018526676A JP 2018526676 A JP2018526676 A JP 2018526676A JP 2018538280 A5 JP2018538280 A5 JP 2018538280A5
Authority
JP
Japan
Prior art keywords
cells
tfr
agent
subject
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2018526676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063604 external-priority patent/WO2017091729A1/en
Publication of JP2018538280A publication Critical patent/JP2018538280A/ja
Publication of JP2018538280A5 publication Critical patent/JP2018538280A5/ja
Abandoned legal-status Critical Current

Links

JP2018526676A 2015-11-23 2016-11-23 免疫応答を調節するための組成物及び方法 Abandoned JP2018538280A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562258876P 2015-11-23 2015-11-23
US62/258,876 2015-11-23
US201662300339P 2016-02-26 2016-02-26
US62/300,339 2016-02-26
PCT/US2016/063604 WO2017091729A1 (en) 2015-11-23 2016-11-23 Compositions and methods for modulating an immune response

Publications (2)

Publication Number Publication Date
JP2018538280A JP2018538280A (ja) 2018-12-27
JP2018538280A5 true JP2018538280A5 (enExample) 2020-01-09

Family

ID=58763732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526676A Abandoned JP2018538280A (ja) 2015-11-23 2016-11-23 免疫応答を調節するための組成物及び方法

Country Status (6)

Country Link
US (2) US11028364B2 (enExample)
EP (1) EP3380197A4 (enExample)
JP (1) JP2018538280A (enExample)
AU (1) AU2016361569A1 (enExample)
CA (1) CA3005899A1 (enExample)
WO (1) WO2017091729A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2531216B1 (en) * 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
CN117425668A (zh) * 2021-03-16 2024-01-19 国立大学法人大阪大学 SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003002A2 (en) * 2008-07-02 2010-01-07 Board Of Regents, The University Of Texas System Modulation of follicular helper t cells
WO2014074852A1 (en) * 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response

Similar Documents

Publication Publication Date Title
Wang et al. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity
Uhlin et al. Adjunct immunotherapies for tuberculosis
Bachmann et al. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor α and CD62L
US20210338732A1 (en) Adoptive cell transfer and oncolytic virus combination therapy
WO2021019102A3 (en) A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
Lee et al. Nasal delivery of chitosan/alginate nanoparticle encapsulated bee (Apis mellifera) venom promotes antibody production and viral clearance during porcine reproductive and respiratory syndrome virus infection by modulating T cell related responses
JP2015131795A5 (enExample)
JP2015512866A5 (enExample)
Orr et al. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
JP2012021028A5 (enExample)
RU2015107435A (ru) Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
CN115137752A (zh) 用于干细胞移植的方法
JP2015525784A5 (enExample)
JP2015526469A5 (enExample)
DE60332377D1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
KR102122955B1 (ko) 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
JP2018538280A5 (enExample)
JP2014510073A (ja) ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
RU2017124141A (ru) Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение
JP2014516538A5 (enExample)
Hu et al. The profile of T cell responses in bacille calmette–guérin-primed mice boosted by a novel sendai virus vectored anti-tuberculosis vaccine
Grover et al. Heat killed Saccharomyces cerevisiae as an adjuvant for the induction of vaccine-mediated immunity against infection with Mycobacterium tuberculosis
Ji et al. Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis
JP2019508056A5 (enExample)